G-BA finds 'no additional benefit' for Shire's Elvanse

Germany's Federal Joint Committee (G-BA) said ADHD drug Elvanse lisdexamfetamine dimesylate from Shire plc (LSE:SHP; NASDAQ:SHPG) has "no additional benefit" over Strattera atomoxetine from Eli Lilly and Co. (NYSE:LLY) in patients six years and older who failed treatment with methylphenidate -- its approved indication. G-BA's final benefit assessment is in line with a September preliminary assessment from Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) (see BioCentury Extra, Sept. 3). ...